The benefit of digoxin was driven by reduced risk of new-onset or worsening HF hospitalizations, just like its benefit in ...

A sensitive (0.2 ng per milliliter), precise (standard deviation 3 to 4 per cent), and specific radioimmunoassay for serum digoxin concentration has been developed. Levels are determined by ...

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...

Heart failure (HF) is the leading cause of hospitalization among older adults. Digoxin has been shown to reduce hospitalization due to worsening HF. However, at the commonly prescribed dose of 0.25 mg ...

In patients with heart failure with reduced ejection fraction (HFrEF) who have an implantable cardioverter-defibrillator (ICD), the use of digoxin may increase the risk of ventricular tachyarrhythmia ...

Please provide your email address to receive an email when new articles are posted on . At 6 months, quality of life in patients with permanent atrial fibrillation and symptomatic HF treated with ...

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience new-onset or worsening heart failure during a two-year follow-up compared with ...

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, a cardiac glycoside associated in modern medicine with Digitalis species ...